Viral Vector Supply Chain
& AAV Gene Therapy Procurement
End-to-end supply chain solutions specifically designed for the unique complexity
of AAV gene therapy manufacturing: from plasmid and helper virus sourcing through CDMO selection, clinical supply planning, and commercial launch.
End-to-End Solutions Reliable Viral Vector Supply from Development to Commercialization
DES Pharma provides end-to-end supply chain solutions designed to ensure reliable, cost-effective AAV gene therapy drug product supply. From early development to commercial launch, we create supply strategies tailored to your viral vector program’s unique requirements, including the highly specialized raw materials, constrained CDMO landscape, and complex cold chain logistics specific to gene therapy.
Gene therapy supply chains differ fundamentally from small molecule and even standard biologic supply. Low production yields, limited qualified suppliers for critical materials, and small patient populations require a purpose-built strategy, not a generic pharmaceutical supply chain model.
Viral Vector-Specific Raw Material Sourcing
Specialized procurement capabilities for AAV gene therapy manufacturing materialsThis includes plasmids (transgene, rep/cap, helper plasmid), helper virus systems (adenovirus, baculovirus components), and chromatography resins (AAVX, AVB Sepharose, AEX/CEX resins for AAV purification). We manage the entire supplier qualification and quality agreement lifecycle for gene therapy raw materials.
Proven Expertise
Our Core Viral Vector
Supply Chain Services
Comprehensive procurement and supply chain management services built around the specific requirements of AAV gene therapy and viral vector manufacturing.
Raw Material Planning & Risk Assessment
Bill of materials analysis, safety stock strategy, and AAV-specific critical material qualification
- Bill of Materials (BOM) risk assessment for viral vector manufacturing
- Plasmid GMP manufacturing vendor qualification and selection
- Adventitious agent testing material sourcing (cell substrates, assay kits)
- Animal-free / chemically-defined media sourcing strategy
- Safety stock assessment and recommendations for long-lead-time materials
- Chromatography resin qualification (AAVX, AVB Sepharose, Capto, etc.)
- Single-use bioprocess bag and filter supplier qualification
- Consumables sourcing and vendor diversification
Drug Product Supply Planning
Clinical demand forecasting, capacity allocation, and end-to-end supply chain map for AAV drug product
- Supply chain maps (end-to-end visualization for viral vector products)
- Manufacturing capacity allocation and yield-adjusted planning
- Fill and finish solutions (aseptic fill, cold chain, ultra-low temperature)
- Patient access logistics for commercial gene therapy products
- Demand planning and clinical trial enrollment forecasting
- End-to-end supply chain risk assessment (FMEA-based)
- Drug product packaging and labeling for gene therapy
- Small-batch clinical supply strategy for rare disease programs
Contract Manufacturer (CDMO) Selection for AAV
RFP management, technical due diligence, and CDMO qualification for viral vector manufacturing
- AAV CDMO landscape assessment and capability mapping
- Technical due diligence on CDMO AAV manufacturing platforms
- Capacity and timeline feasibility assessment
- Category strategy management for manufacturing partnerships
- Request for Proposal (RFP) process management and scoring
- GMP compliance and FDA inspection history evaluation
- Vendor qualification audits (manufacturing, analytical, QC)
- Tech transfer feasibility and cost modeling
Product Storage & Biorepository Management
Cold chain strategy, warehouse management, and 3PL solutions for AAV gene therapy products
- Ultra-low temperature (-80°C, liquid nitrogen) cold chain strategy
- ERP implementation for gene therapy supply tracking
- Chain of identity (COI) and chain of custody (COC) for personalized medicine
- Stability storage program management
- Warehouse management and inventory control systems
- 3rd Party Logistics (3PL) solutions and qualification
- Cell and gene therapy biorepository design and management
- Risk management and business continuity planning
Contract Negotiations & Alliance Management
Vendor contract setup, cost modeling, and KPI governance for CDMO partnerships
- Manufacturing services agreement (MSA) negotiation support
- Cost modeling for viral vector manufacturing at clinical and commercial scale
- Governance charter design for critical CDMO relationships
- KPI definition, tracking, and escalation protocols
- Quality agreement (QA) development and review
- Vendor management and performance monitoring systems
- Alliance management for multi-party gene therapy supply chains
Gene Therapy Supply Chain Expertise Navigating the Unique Complexity of Viral Vector Supply
AAV gene therapy supply chains are fundamentally different from conventional biologics. The limited landscape of qualified AAV CDMOs, the complexity of multi-plasmid raw material systems, ultra-low temperature cold chain requirements, and the need for chain-of-identity in autologous programs create challenges that standard pharmaceutical supply chain frameworks are not equipped to address.
DES Pharma has built our viral vector supply chain practice around these unique realities. We understand the critical path dependencies between plasmid delivery, CDMO slot availability, and clinical trial enrollment. We build supply strategies that protect programs from the common failure modes that delay gene therapy programs by months or years.
Whether you’re selecting your first CDMO partner, navigating a platform technology transfer, or building commercial supply chain infrastructure ahead of a BLA submission, DES Pharma delivers the specialized expertise and industry relationships to execute.
Critical Raw Material Risk Management
Single-source supplier identification, dual-sourcing strategy, safety stock models, and supply disruption contingency plans for GMP plasmids and chromatography resins
Ultra-Low Temperature Cold Chain Design
-80°C and liquid nitrogen supply chain design, validated shipping containers, qualified 3PL networks, and stability protocol alignment for gene therapy products
CDMO Selection & Technical Due Diligence
Structured AAV CDMO assessment across platform capabilities, GMP compliance, regulatory inspection history, and slot availability for your development timeline
Demand Planning for Rare Disease Programs
Small-batch clinical supply planning, patient registry-based enrollment forecasting, and commercial yield-adjusted demand models for ultra-orphan gene therapies
Viral Vector Raw Material Risk Framework
Key Material Risk Categories
for AAV Manufacturing
Understanding the supply risk profile of your critical starting materials is the
foundation of a resilient viral vector supply chain strategy.
| Raw Material | Supply Complexity | Lead Time | DES Pharma Strategy |
|---|---|---|---|
| GMP Plasmids (transgene, rep/cap, helper) | HIGH | 12–20 weeks | Early vendor qualification, dual-sourcing, rolling safety stock |
| Affinity Resins (AAVX, AVB Sepharose) | HIGH | 8–16 weeks | Lifetime studies, resin reuse qualification, alternative resin validation |
| Serum-Free Cell Culture Media | MEDIUM | 4–8 weeks | Lot-to-lot qualification, safety stock, chemically defined alternatives |
| Single-Use Bioprocess Components | MEDIUM | 4–12 weeks | Leachables/extractables qualification, validated alternatives |
| Baculovirus / Helper Virus Systems | HIGH | 16–24 weeks | In-house generation capability assessment, MCB/WCB backup strategy |
| Cryoprotectants & Formulation Excipients | LOW | 2–4 weeks | Standard compendial sourcing with CoA review and supplier qualification |
Our Approach Tailored Solutions, Immediate Impact
Three core principles that differentiate DES Pharma’s supply chain practice for gene therapy and biologics programs.
Customized Process
We listen, discuss, and understand your program's specific needs, applying our industry knowledge and CDMO network to deliver a rapid, customized viral vector supply strategy from development to commercialization.
Forward-Thinking Experts
Innovation is central to how we work. Our team of high-performing professionals provides access to the right skills and industry relationships for your gene therapy program's specific supply chain needs.
Immediate Value
We create immediate value through robust process implementation, optimizing cost, quality, and supply reliability, protecting your clinical timeline and commercial launch trajectory.
Get Started
Build a Resilient Viral
Vector Supply Chain Today
Protect your AAV gene therapy program from supply disruptions and CDMO delays.